Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 3/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | SMPD1 | P17405 | 5/20 | 0.33 |
| ▸ | CTSK | P43235 | 4/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2239348 | 0.94 | FDPS (0.40) | FDPSSMPD1 | |
| SCHEMBL28432671 | 0.85 | TDP1 (0.44) | DGAT1 | |
| SCHEMBL1251054 | 0.83 | CYP4F2 (0.43) | DGAT1 | |
| SCHEMBL30690424 | 0.83 | DGAT1 (0.35) | DGAT1 | |
| SCHEMBL3996360 | 0.82 | FDPS (0.39) | FDPSDGAT1SMPD1CTSKLMNA | |
| SCHEMBL29503885 | 0.82 | FDPS (0.39) | FDPSDGAT1SMPD1CTSKLMNA | |
| SCHEMBL28489181 | 0.82 | CYP4F2 (0.44) | FDPSDGAT1CTSKCTSSCA12 | |
| SCHEMBL27795979 | 0.81 | DGAT1 (0.43) | DGAT1CA12CA1CA7CA14 | |
| SCHEMBL1115801 | 0.81 | DGAT1 (0.43) | DGAT1CA12CA1CA7CA14 | |
| SCHEMBL27775120 | 0.81 | DGAT1 (0.43) | DGAT1CA12CA1CA7CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4637832-A1 | CONJUGATES COMPRISING A PHOSPHORUS(V) MOIETY AND A DRUG | Tubulis GmbH (DE) | 2025-10-29 | — | — | EP | disclosed |
| US-20240269313-A1 | CONJUGATES COMPRISING A PHOSPHORUS(V) MOIETY AND A DRUG | TUBULIS GMBH (DE) | 2024-08-15 | — | — | US | disclosed |
| WO-2024133845-A1 | CONJUGATES COMPRISING A PHOSPHORUS(V) MOIETY AND A DRUG | TUBULIS GMBH (DE) | 2024-06-27 | — | — | WO | disclosed |
| EP-1098659-A4 | LIBRARIES OF POLYHYDROXAMATES AND THEIR ANALOGS | METAPHORE INC (US) | 2004-11-24 | — | — | EP | disclosed |
| EP-1098659-A2 | LIBRARIES OF POLYHYDROXAMATES AND THEIR ANALOGS | Metaphore, Inc. (US) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000004868-A2 | LIBRARIES OF POLYHYDROXAMATES AND THEIR ANALOGS | METAPHORE, INC. (US) | 2000-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240269313-A1 | CONJUGATES COMPRISING A PHOSPHORUS(V) MOIETY AND A DRUG | PTH1R, SELPLG, CALCR | FDPS 1426/4885DGAT1 4539/4885SMPD1 3075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.